Landmark analysis after 1 year of vemurafenib therapy showed significantly higher overall survival (P = .02) of patients who had no relapse during the first year of treatment. See Figure 2B in the article by Handa et al, that begins on page 2663.
Landmark analysis after 1 year of vemurafenib therapy showed significantly higher overall survival (P = .02) of patients who had no relapse during the first year of treatment. See Figure 2B in the article by Handa et al, that begins on page 2663.
